Shionogi
shionogi.comTotal trials
76
Active
9
Phase 3
22
Total enrollment
35,061
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Naldemedine | — | — | — | — | 7 | ||
| BPN14770 | — | — | — | — | 4 | ||
| S-337395 | — | — | — | — | 2 | ||
| S-531011 | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | — | — | 1 | |
| S-606001 | — | — | — | — | — | 1 | |
| Sivopixant | — | — | — | — | — | 1 | |
| Acetazolamide | — | — | — | — | — | 1 | |
| SASS-001 | — | — | — | — | — | 1 | |
| Redasemtide | — | — | — | — | — | 1 | |
| S-892216-PO | — | — | — | — | — | 1 | |
| S-892216-LAI | — | — | — | — | — | 1 |
Next readouts
- 2026-06-05
- 2026-06-15
- 2026-06-30
- 2026-12-30
- 2026-12-31
- 2027-05-26
- 2027-08-08
- 2028-05-31
- 2030-01-31
Top conditions
- Obesity7
- Atrophy6
- Vaginal Diseases6
- Opioid-induced Constipation4
- Healthy Volunteers3
- Healthy Volunteer3
- Renal Impairment3
- Healthy Participants3
Frequently asked questions about Shionogi
- How many clinical trials does Shionogi have on ClinicalTrials.gov?
- Shionogi is listed as the lead sponsor on 76 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shionogi's trials are in Phase 3?
- 22 of Shionogi's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does Shionogi focus on?
- Shionogi's most-studied conditions on ClinicalTrials.gov are Obesity, Atrophy, Vaginal Diseases, Opioid-induced Constipation, Healthy Volunteers.
- When are Shionogi's next clinical trial readouts?
- Shionogi has 9 upcoming primary-completion readouts tracked here; the soonest is “A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls”, expected around 2026-06-05.